<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03318380</url>
  </required_header>
  <id_info>
    <org_study_id>17F.310</org_study_id>
    <nct_id>NCT03318380</nct_id>
  </id_info>
  <brief_title>Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis</brief_title>
  <official_title>Contrast-Enhanced Ultrasound Evaluation of Focal Liver Lesions in Patients With Cirrhosis or Other Risk Factors for Developing HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies how well contrast-enhanced ultrasound imaging works in diagnosing
      liver cancer in patients with cirrhosis. Diagnostic procedures, such as contrast-enhanced
      ultrasound imaging, may help find and diagnose liver cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the sensitivity, specificity, positive and negative predictive values of
      contrast-enhanced ultrasound (CEUS) for diagnosis of hepatocellular carcinoma (HCC) in
      patients at risk for HCC in a multicenter setting.

      SECONDARY OBJECTIVES:

      I. To validate CEUS Liver Imaging Reporting and Data System (LI-RADS) and determine the
      prevalence of HCC in each CEUS LI-RADS category.

      II. To evaluate inter-reader reliability of CEUS for HCC diagnosis. III. To evaluate
      covariates that might limit diagnostic performance of CEUS for HCC diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval 95% confidence interval for HCC diagnosis using CEUS LR-5 classification</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A value of 67% for sensitivity is expected based on recent meta-analysis studies of CEUS for focal liver mass characterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A value of 91% for specificity is expected based on recent meta-analysis studies of CEUS for focal liver mass characterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A value of 93% for Positive Predicative Value is expected based on recent meta-analysis studies of CEUS for focal liver mass characterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative Predictive Value of contrast-enhanced ultrasound evaluation (CEUS) for diagnosis of Hepatocellular cancer using a 95% confidence interval</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A value of 60% for Negative predictive value is expected based on recent meta-analysis studies of CEUS for focal liver mass characterization.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive sulfur hexafluoride IV and undergo CEUS imaging over 10 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dynamic Contrast-Enhanced Ultrasound Imaging</intervention_name>
    <description>Undergo CEUS</description>
    <arm_group_label>Diagnostic Contrast-Enhanced Ultrasound Imaging (CEUS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of making informed decisions regarding his/her treatment

          -  Have known cirrhosis or other risk factors for HCC, based on American Association for
             the Study of Liver Diseases (AASLD) and European Association for the Study of the
             Liver (EASL) guidelines (applicable in each site jurisdictions)

          -  Patients with untreated focal liver observations on liver ultrasound or multiphase
             contrast-enhanced CT or MRI performed as part of clinical standard of care within 4
             weeks before patient enrollment.

        OR

        â€¢ Patients with untreated focal liver observations scheduled for follow-up multiphase
        contrast-enhanced CT or MRI, biopsy or surgical excision as part of clinical standard of
        care. CEUS should be performed within 4 weeks before or after follow-up imaging or within 4
        weeks before biopsy or surgical excision.

        Exclusion Criteria:

          -  Patients who are pregnant or lactating

          -  Patients with focal liver observations less than 5 mm or greater than 5 cm in size

          -  Patients with contraindications to CEUS

          -  Patients with contraindications to both CT and MRI

          -  Patients who are medically unstable, terminally ill, or whose clinical course is
             unpredictable

          -  Liver nodule previously treated with trans-arterial or thermal ablation

          -  Patients who have received an investigational drug in the 30 days before CEUS, or will
             receive one within 72 hour after their CEUS exam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrej Lyshchik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrej Lyshchik, MD, PhD</last_name>
    <phone>215-503-0587</phone>
    <email>Andrej.Lyshchik@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuko Kono, MD</last_name>
      <email>ykono@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Yuko Kono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Cancer Center at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrej Lyshchik, MD, PhD</last_name>
      <email>Andrej.Lyshchik@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuchi Rodgers, MD</last_name>
      <phone>215-456-3439</phone>
      <email>rodgersS@einstein.edu</email>
    </contact>
    <investigator>
      <last_name>Shuchi Rodgers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Wile, MD</last_name>
      <email>geoffrey.wile@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Wilde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Finch, MD</last_name>
      <email>lisa.finch@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Lisa Finch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Wilson, MD</last_name>
      <email>stephanie.wilson@ahs.ca</email>
    </contact>
    <investigator>
      <last_name>Stephanie Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Piscaglia, MD</last_name>
      <email>fabio.piscaglia@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Piscaglia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Sidhu, MD</last_name>
      <email>paulsidhu@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul Sidhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kimmelcancercenter.org/cancer-center.html</url>
    <description>Sidney Kimmel Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Thomas Jefferson University Hospital</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2017</study_first_submitted>
  <study_first_submitted_qc>October 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

